PubMed

Clinical significance of BRAF mutations in metastatic melanoma.

Chang DZ, Panageas KS, Osman I, Polsky D, Busam K, Chapman PB.

J Transl Med. 2004 Dec 21;2(1):46.PMID: 15613230 [PubMed - as supplied by publisher]Related articlesFree article

Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis.

Houben R, Becker JC, Kappel A, Terheyden P, Bröcker EB, Goetz R, Rapp UR.

J Carcinog. 2004 Mar 26;3(1):6.PMID: 15046639 [PubMed - as supplied by publisher]Related articlesFree article

Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis.

Willmore-Payne C, Holden JA, Tripp S, Layfield LJ.

Hum Pathol. 2005 May;36(5):486-93.PMID: 15948115 [PubMed - indexed for MEDLINE]Related articles

BRAF and NRAS mutations in melanoma and melanocytic nevi.

Poynter JN, Elder JT, Fullen DR, Nair RP, Soengas MS, Johnson TM, Redman B, Thomas NE, Gruber SB.

Melanoma Res. 2006 Aug;16(4):267-73.PMID: 16845322 [PubMed - indexed for MEDLINE]Related articles

NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.

Edlundh-Rose E, Egyházi S, Omholt K, Månsson-Brahme E, Platz A, Hansson J, Lundeberg J.

Melanoma Res. 2006 Dec;16(6):471-8.PMID: 17119447 [PubMed - indexed for MEDLINE]Related articles

BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival.

Akslen LA, Angelini S, Straume O, Bachmann IM, Molven A, Hemminki K, Kumar R.

J Invest Dermatol. 2005 Aug;125(2):312-7.PMID: 16098042 [PubMed - indexed for MEDLINE]Related articles

Improving melanoma classification by integrating genetic and morphologic features.

Viros A, Fridlyand J, Bauer J, Lasithiotakis K, Garbe C, Pinkel D, Bastian BC.

PLoS Med. 2008 Jun 3;5(6):e120.PMID: 18532874 [PubMed - indexed for MEDLINE]Related articlesFree article

Prognostic significance of tumor iNOS and COX-2 in stage III malignant cutaneous melanoma.

Johansson CC, Egyházi S, Masucci G, Harlin H, Mougiakakos D, Poschke I, Nilsson B, Garberg L, Tuominen R, Linden D, Stolt MF, Hansson J, Kiessling R.

Cancer Immunol Immunother. 2009 Jul;58(7):1085-94. Epub 2008 Nov 28.PMID: 19039588 [PubMed - indexed for MEDLINE]Related articles

BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs.

Wong CW, Fan YS, Chan TL, Chan AS, Ho LC, Ma TK, Yuen ST, Leung SY; Cancer Genome Project.

J Clin Pathol. 2005 Jun;58(6):640-4. Review.PMID: 15917418 [PubMed - indexed for MEDLINE]Related articlesFree article

Lack of cytoplasmic ERK activation is an independent adverse prognostic factor in primary cutaneous melanoma.

Jovanovic B, Kröckel D, Linden D, Nilsson B, Egyhazi S, Hansson J.

J Invest Dermatol. 2008 Nov;128(11):2696-704. Epub 2008 May 29.PMID: 18509361 [PubMed - indexed for MEDLINE]Related articlesFree article

BRAF somatic mutations in malignant melanoma and melanocytic naevi.

Thomas NE.

Melanoma Res. 2006 Apr;16(2):97-103. Review.PMID: 16567964 [PubMed - indexed for MEDLINE]Related articles

Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma.

Akslen LA, Puntervoll H, Bachmann IM, Straume O, Vuhahula E, Kumar R, Molven A.

Melanoma Res. 2008 Feb;18(1):29-35.PMID: 18227705 [PubMed - indexed for MEDLINE]Related articles

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.PMID: 17993229 [PubMed - indexed for MEDLINE]Related articles

Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma.

Thomas NE, Edmiston SN, Alexander A, Millikan RC, Groben PA, Hao H, Tolbert D, Berwick M, Busam K, Begg CB, Mattingly D, Ollila DW, Tse CK, Hummer A, Lee-Taylor J, Conway K.

Cancer Epidemiol Biomarkers Prev. 2007 May;16(5):991-7.PMID: 17507627 [PubMed - indexed for MEDLINE]Related articlesFree article

Analysis of BRAF mutation in primary and metastatic melanoma.

Libra M, Malaponte G, Navolanic PM, Gangemi P, Bevelacqua V, Proietti L, Bruni B, Stivala F, Mazzarino MC, Travali S, McCubrey JA.

Cell Cycle. 2005 Oct;4(10):1382-4. Epub 2005 Oct 13.PMID: 16096377 [PubMed - indexed for MEDLINE]Related articlesFree article

Characterization of candidate gene copy number alterations in the 11q13 region along with BRAF and NRAS mutations in human melanoma.

Lázár V, Ecsedi S, Szöllosi AG, Tóth R, Vízkeleti L, Rákosy Z, Bégány A, Adány R, Balázs M.

Mod Pathol. 2009 Oct;22(10):1367-78. Epub 2009 Jul 24.PMID: 19633643 [PubMed - indexed for MEDLINE]Related articles

Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma.

Goel VK, Lazar AJ, Warneke CL, Redston MS, Haluska FG.

J Invest Dermatol. 2006 Jan;126(1):154-60.PMID: 16417231 [PubMed - indexed for MEDLINE]Related articlesFree article

Further delineation of the phenotype resulting from BRAF or MEK1 germline mutations helps differentiate cardio-facio-cutaneous syndrome from Costello syndrome.

Gripp KW, Lin AE, Nicholson L, Allen W, Cramer A, Jones KL, Kutz W, Peck D, Rebolledo MA, Wheeler PG, Wilson W, Al-Rahawan MM, Stabley DL, Sol-Church K.

Am J Med Genet A. 2007 Jul 1;143A(13):1472-80.PMID: 17551924 [PubMed - indexed for MEDLINE]Related articles

BRAF kinase in melanoma development and progression.

DeLuca AM, Srinivas A, Alani RM.

Expert Rev Mol Med. 2008 Feb 18;10:e6. Review.PMID: 18279546 [PubMed - indexed for MEDLINE]Related articles

Gene expression signature associated with BRAF mutations in human primary cutaneous melanomas.

Kannengiesser C, Spatz A, Michiels S, Eychène A, Dessen P, Lazar V, Winnepenninckx V, Lesueur F, Druillennec S, Robert C, van den Oord JJ, Sarasin A, Bressac-de Paillerets B; EORTC Melanoma group.

Mol Oncol. 2008 Apr;1(4):425-30. Epub 2008 Jan 12.PMID: 19383316 [PubMed - indexed for MEDLINE]Related articles